2nd Conference on Skeletal Biology and Medicine
Wednesday, April 25, 2007 - Saturday, April 28, 2007
Presented by Mount Sinai School of Medicine and the New York Academy of Sciences
This is a CME-Accredited program.
Scientific Director and Chair
Mone Zaidi, MD, PhD
Mount Sinai School of Medicine
New York, New York
Gerard Karsenty, MD, PhD
New York, New York
Steven L. Teitelbaum, MD
Washington University School of Medicine
St. Louis, Missouri
Insights into the mechanisms of bone development and restructuring including cellular and mechanical factors, receptors, and signaling pathways have contributed to our understanding of both normative and pathologic states of bone and the skeleton. Bone cells undergo dynamic processes whereby they are influenced by numerous genetic factors and cellular mediators. Recent findings are shaping therapeutic directions to focus on multiple modes of intervention involving anti-resorptive treatments and anabolic agents. Also significant is the role that other physiological systems or disease states such as the immune system, inflammation, infection, and cancer have on bone and musculoskeletal health. A better understanding of the fundamentals of skeletal biology, the pathophysiology associated with skeletal disease and the molecular and genetic basis for some of these disorders will impact on the ability to find effective treatments. This conference will combine basic, clinical, and translational research in a forum designed to provide the most current information on aspects of skeletal development and its relationship to bone disease and its treatment.
Acknowledgement of Conference Contributors
This activity has been made possible in part by educational
grants from: Amgen Inc., Genzyme Corporation, Eli Lilly & Company, Embryon, Merck Research Laboratories, National Institute of Arthritis and Musculoskeletal and Skin Diseases - NIH, Novartis Pharmaceuticals, NPS Pharmaceuticals, Procter & Gamble Alliance for Better Bone Health, Roche Pharmaceuticals, Sanofi-Aventis, Diane Wolf Foundation, Erving & Joyce Wolf Foundation, and Wyeth Pharmaceuticals.
Funding for this conference was made possible (in part) by grant number 1 R13 AR055047-01 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH). The views expressed in written conference materials or publications and by speakers, session chairs and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.